Tubulis Revenue and Competitors
Estimated Revenue & Valuation
- Tubulis's estimated annual revenue is currently $11.3M per year.
- Tubulis's estimated revenue per employee is $155,000
- Tubulis's total funding is $216M.
Employee Data
- Tubulis has 73 Employees.
- Tubulis grew their employee count by 35% last year.
Tubulis's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, Member the Advisory Board | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | SVP and Head Clinical Operations | Reveal Email/Phone |
4 | Sr Scientist Early Discovery | Reveal Email/Phone |
Tubulis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Tubulis?
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
keywords:N/A$216M
Total Funding
73
Number of Employees
$11.3M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 73 | 9% | N/A |
#2 | $14.5M | 73 | 20% | N/A |
#3 | N/A | 74 | 28% | N/A |
#4 | $10.7M | 74 | 42% | N/A |
#5 | $9.7M | 74 | 51% | N/A |